SCHEMBL6567747

SCHEMBL6567747

CCOc1c(CCCO)cc(C)cc1C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 1/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
HIF1A Q16665 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP2D6 P10635 2/20 0.37
CYP3A4 P08684 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CA2 P00918 1/20 0.37
POLB P06746 1/20 0.37
TYR P14679 1/20 0.37
RARG P13631 2/20 0.33
RXRA P19793 1/20 0.33
PPARG P37231 1/20 0.33
VCAM1 P19320 2/20 0.33
RARA P10276 1/20 0.32
RARB P10826 1/20 0.32
CYP4F2 P78329 1/20 0.31
CYP4A11 Q02928 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6568857 0.85 RXRA (0.43) CYP2C9CYP2C19CYP3A4RARGRXRA
SCHEMBL6567754 0.85 HSPA5 (0.44) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL8430289 0.83 CYP4F2 (0.38) HSPA5CYP2D6CYP3A4POLBVCAM1
SCHEMBL7943147 0.82 VCAM1 (0.37) CYP2D6CYP3A4ALDH1A1POLBVCAM1
SCHEMBL6568685 0.81 HSPA5 (0.42) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL7792696 0.80 NPSR1 (0.42) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL6565876 0.78 TNKS2 (0.39) HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2
SCHEMBL6567344 0.78 HTR1D (0.34) CYP2C9CYP2C19CYP2D6HSD17B10ALDH1A1
SCHEMBL6567734 0.78 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1CA2RARGRARA
SCHEMBL6567740 0.77 CYP4F2 (0.37) SMN1; SMN2ALDH1A1VCAM1CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1484334-A2 Process for producing phosphite SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-12-08 EP disclosed
US-20040225145-A1 Process for producing phosphite SUMITOMO CHEMICAL COMPANY, LIMITED 2004-11-11 US disclosed
EP-0823435-B1 Phosphites, process for producing the same and their use SUMITOMO CHEMICAL CO (JP) 2001-11-21 EP disclosed
US-6242514-B1 CYCLIC PHOSPHATE OR PHOSPHONATE; HEAT AND OXIDATION STABILIZER ESPECIALLY FOR OLEFIN POLYMERS AND ENGINEERING THERMOPLASTICS SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2001-06-05 US disclosed
US-5914361-A IMPART HEAT STABILITY TO ORGANIC MATERIALS, INCLUDING POLYOLEFINS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-06-22 US disclosed
US-5889095-A OXYGEN AND HEAT RESISTANCE SUMITOMO CHEMICAL COMPANY, LTD. (JP) 1999-03-30 US disclosed
EP-0823435-A2 Phosphites, process for producing the same and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040225145-A1 Process for producing phosphite PHOSPHO1, PLCG1, PLCG2 HSPA5 4485/4885CYP2C9 1692/4885CYP2C19 1924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.